摘要
目的评价坎格列净对2型糖尿病患者血糖及血脂的影响。方法计算机检索万方数据库、中国生物医学文献数据库、中国期刊全文数据库、维普数据库以及英文数据库SCI、Pubmed、Embase数据库,纳入坎格列净治疗2型糖尿病的随机对照临床研究文献,对收集的文献进行质量评价,使用STATA 14.0软件对提取的数据进行Meta分析。结果最终共纳入14篇文献,总病例数为8 386例。Meta分析显示,与空白对照组比较,坎格列净能够显著提高糖化血红蛋白(HbA1c)<7%的达标例数,显著降低甘油三酯水平,提高高密度脂蛋白-胆固醇水平,但也同时提高低密度脂蛋白-胆固醇水平,差异均有统计学意义(P<0.01),但低密度脂蛋白/高密度脂蛋白比值差异无统计学意义(P>0.05)。结论坎格列净可提高2型糖尿病患者HbA1c达标率,并能有效改善血脂代谢。
Objective To evaluate the effect of canagliflozin on blood glucose and lipids in patients with type 2 diabetes. Methods The canagliflozin clinical trials literatures which were searched from several databases, such as Wanfang Data, CBM, CNKI, VIP, SCI, Pubmed and Embase, were collected. After accessing these literatures, Meta-analysis was conducted by STATA 14.0. Results A total of 14 trials and 8 386 patients were involved in this Meta-analysis. Compared with placebo, canagliflozin could significantly increase the number of patients whose HbAlc<7%, increase the levels of low density lipoprotein-cholesterol(LDL-C) and the high density lipoprotein-cholesterol(HDL-C), decrease the levels of triglycerides(P<0.01), but there was no difference in LDL/HDL ratio(P>0.05). Conclusion Canagliflozin can significantly increase the standard-reaching rate of Hb A1 c and improve blood lipids metabolism in the patients with type 2 diabetes.
出处
《世界临床药物》
CAS
2017年第4期257-267,共11页
World Clinical Drug
